When AI Meets Accounting

AI Costs and Intangible Asset Treatment for Sponsors and CROs

Karen McDaniel
3/13/2026

This article was originally published Feb. 13, 2026, in Clinical Leader.

As sponsors and CROs increasingly integrate AI into clinical trials, data management, and analytics, finance leaders across both organizations face a pressing challenge: how to account for AI-related costs under evolving U.S. generally accepted accounting principles (GAAP).

The life sciences ecosystem is focused not only on deploying AI effectively but also on mitigating risks and exposures, such as identifying hallucinations and verifying the reliability of AI data, output, and processes. The types of AI technologies used vary across different departments and at different stages of the contract life cycle. Sponsors and CROs using AI should be aware of some of the common use cases for currently emerging AI, understand how financial reporting treatment can differ due to complexities in the accounting rules and the related impacts, and be clear on what finance professionals should be thinking about as they embark on the AI journey.

Read the full article on Clinical Leader
When AI Meets Accounting: AI Costs and Intangible Asset Treatment for Sponsors and CROs
Read the article
Guidance for life sciences
Get help navigating risk, compliance, supply chain, and growth opportunities.

Contact us


Karen McDaniel
Karen McDaniel
Partner, Audit & Assurance, Crowe LLP
Partner, Crowe Advisory LLC

Related insights

loading gif
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.